Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Nektar Therapeutics
- Study ID
- NCT04410445
- Phase
- PHASE3
- Status
- Terminated
Conditions
- Melanoma
- Melanoma (Skin)
- Melanoma Stage III
- Melanoma Stage IV
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bempegaldesleukin — BIOLOGICALSpecified dose on specified days
- Nivolumab — BIOLOGICALSpecified dose on specified days
Study Details
The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.
Key Dates
- Start date
- Jul 27, 2020
- Status verified
- Mar 2023
- Primary completion
- Sep 22, 2022
- Completion
- Sep 22, 2022
Study Design
- Enrollment
- 765 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Combination of bempegaldesleukin (NKTR-214) + nivolumabArm A: Participants will receive bempegaldesleukin (NKTR-214) IV in combination with nivolumab every 3 weeks.
- Active Comparator: NivolumabArm B: Participants will receive nivolumab IV alone every 4 weeks.
Primary Outcome Measure
Recurrence-free Survival (RFS) by Blinded Independent Central Review (BICR) of Bempegaldesleukin Plus Nivolumab Versus Nivolumab Alone. [ Time Frame: Up to 21 months ]
Locations (62)
Find similar trials in Scottsdale, AZ
By condition
By specialty
Related Studies
- Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of TreatmentRecruiting · Vanderbilt-Ingram Cancer Center · Nashville, Tennessee
- A Phase I/II Trial of Vemurafenib and Metformin to Melanoma PatientsPHASE1/PHASE2 · Recruiting · University of Louisville · Louisville, Kentucky
- Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy ProgramRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- In Vivo Real-time Detection of Circulating Melanoma CellsRecruiting · University of Arkansas · Little Rock, Arkansas